検索結果

ntagonist (development code: SJP-0132) discovered by Mochida Pharmaceutical Co., Ltd. (Head office: Tokyo, Japan; President: Mr. Naoyuki Mochida; hereinafter: Mochida) and licensed to Senju as an eye ...

ntagonist (development code: SJP-0132) discovered by Mochida Pharmaceutical Co., Ltd. (Head office: Tokyo, Japan; President: Mr. Naoyuki Mochida; hereinafter: Mochida) and licensed to Senju as an eye ...

Overseas Activities | SENJU Pharmaceutical

h and pharmaceutical development have no borders. We engage in international activities with a view to the future of pharmaceuticals, transcending national and corporate boundaries. As we enter the er...

Medical devices and healthcare | Business Activities | About Senju | SENJU Pharmaceutical

We will contribute to medical care and your health requirements in the new era through medical devices. Today, in the era of the 100-year-life, digital transformation is being promoted in various fiel...

Business Activities | About Senju | SENJU Pharmaceutical

Based on a sense of mission to contribute to the health of the eyes of people around the world, and a development policy that puts top priority on safety, we have always taken a pioneering path in oph...